Patients having HLA-B*5801 gene
Patients having HLA-B*5801 gene are at an increased risk while taking Agout. This gene is mainly present in Han Chinese, Thai, Korean, Japanese or European origin population. There is a risk of developing allergic reactions in such patients. The presence of HLA-B*5801 gene should be tested before starting treatment with Agout in such patients. Agout should not be given to these patients unless there is no other treatment available or taking the benefits outweigh the risk in consideration. The close monitoring of symptoms of the allergic reactions advised in such patients.
Lactose intolerance
Patients with birth defects of lactose intolerance, abnormal absorption of glucose-galactose or the Lapp lactase deficiency are at an increased risk while taking Agout. Agout should not be given to such patients because it contains lactose.
Thyroid disorders
Patients on long-term therapy of Agout are at an increased risk. There is a risk of an increase in thyroid stimulating
hormone (TSH) in such patients. The patients should be cautious while taking Agout.
Uric acid kidney stones
The therapy with Agout can dissolve uric acid kidney stones and may lead to an impact on the ureter.
Xanthine deposition
Patients with
cancer and Lesch-Nyhan
syndrome are at an increased risk while taking Agout. Patients with an increased formation of urate are at an increased risk of xanthine deposition in the urinary tract. Take adequate fluids to increase the production of urine to minimize the risk of xanthine deposition.
Gout attack
Patients with
gout attack are at an increased risk while taking Agout. The occurrence of a gout attack may be increased while taking drugs that increase the excretion of uric acid in the urine with Agout. Colchicine or anti-inflammatory agent are advised to use for one month as
preventive therapy in such patients. If gout attack occurs during Agout therapy, the treatment with this medicine should be continued with usual dose while gout attack is treated with an anti-inflammatory agent.
Decreased functioning of the kidney
Patients with kidney dysfunction taking treatment for heart failure or high blood pressure such as ACE inhibitors or
diuretics are at an increased risk while taking Agout. The incidence of allergic reactions is increased in such patients. The close monitoring and caution are advised in these patients. The dose of Agout should be reduced in such patients.
Allergic reactions
Patients receiving Agout are at increased risk of allergic reactions. Such patients are at an increased risk of allergic reactions such as skin rash, shedding old skin,
hives, red or purple discolored spots on the skin, severe skin reaction (Stevens-Johnson
syndrome), drug-induced reactions (DRESS), inflammation of blood vessels, irreversible liver damage, and can be fatal. Agout should be discontinued if these allergic reactions occur.
Corticosteroids treatment may be given to such patients.
Liver disease
Patients with existing liver disease are at an increased risk when using this medicine. These patients may have reversible liver damage and level of some liver enzymes may also increase. They may develop symptoms like weight loss,
itching, and an eating disorder (anorexia). In such cases, regular monitoring of liver function is recommended. The dose of Agout should be reduced in such patients.
Mercaptopurine and azathioprine
Patients using mercaptopurine and azathioprine are at an increased risk when using Agout. These patients may experience harmful effects. While using 300-600 mg Agout, the dose adjustment of mercaptopurine and azathioprine is required and a low dose of these drugs should be used.